Anavex Life Sciences Corp (AVXL)

[bas2020]

2-73 patent (#9,180,106) issued Nov. 10, 2015.

Can someone provide additional insights into the scope of this patent? In the claims section, it mentions melanoma; however, the body of the patent seems to make a broader claim, as excerpted below... Do patents have to be written explicitly for each indication (i.e. Alz) or just describe the MoA and list the applicable indications it claims to address?

Field of the Invention

The present invention relates to sigma(a) receptors ligands with anti-apoptotic and/or pro-apoptotic properties for use in connection with exhibiting prototypical cytoprotective properties associated with cytoregenerative activity developed by antagonism of the endoplasmic reticulum stress (ER stress) via activation of the sigma receptors in the connecting membrane between ER and mitochondrion.

...having analgesic activity against neuropathic pain, acting synergistically with clinically used anticancer drugs and antagonizing neuropathic pain induced by the anticancer drugs, pharmaceuticals with cytoprotective activity against pathogenesis of cytodegenerative diseases, pharmaceuticals with cytoprotective and cytoregenerative activity, and pharmaceuticals with protective activity against the pathogenesis of inflammatory and neuropathic pain.

...the invention is not limited in its application to the details of construction and to the arrangements of the components set forth in the following description or illustrated in the drawings. The invention is capable of other embodiments and of being practiced and carried out in various ways.

Thus, in contrast to the precedent patents of the inventor, the above invention displaced the area of the putative application of these molecules from the symptomatic to the therapeutic use because, specially for the cytoprotecting and cytoregeneratingi properties of the following claims the activity of the molecules concern the intracellular targets and pathways of pathogenesis and not the activity of superficial cell membrane receptors, as it is usually the case with the symptomatic drugs: neuroleptics, anti depressive drugs and cholinergics for, respectively, psychosis, depression and Alzheimer.

http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9180106.PN.&OS=PN/9180106&RS=PN/9180106